Device Trial Radar · NCT05855135
Assessment of Combined CCM and ICD Device in HFrEF
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
May 17, 2023
Primary completion
Dec 31, 2025
Study completion Jul 2027
Sponsor
- Lead sponsor
- Impulse DynamicsNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 11, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%). Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.
Conditions
- Heart Failure
- Heart Failure With Reduced Ejection Fraction
- Implantable Defibrillator User
- CCM Therapy
- Non-ischemic Cardiomyopathy
- Ischemic Cardiomyopathy
- Sudden Cardiac Arrest
- Arrhythmias, Cardiac
- Ventricular Tachycardia
- Ventricular Fibrillation
Interventions
OPTIMIZER® Integra CCM-D System (Treatment Arm)Device
The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a "Cardiac Contractility Modulation - Defibrillator". All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Device Effectiveness in Converting Induced Ventricular Fibrillation (Primary Efficacy Objective)Time frame: Implant
- Device-related Complications (Primary Safety Objective)Time frame: Implant to 6 months
Locations
59 sites in 1 country. Site status is shown where the registry gives one.
Phoenix Heart
Glendale, Arizona
CardioVascular Associates of Mesa
Mesa, Arizona
Southwest Cardiovascular Associates
Mesa, Arizona
56 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.